Browse by UCL people
Group by: Type | Date
Jump to: Article
Number of items: 8.
Article
Dinneen, E;
Allen, C;
Strange, T;
Heffernan-Ho, D;
Banjeglav, J;
Lindsay, J;
Mulligan, JP;
... Punwani, S; + view all
(2022)
Negative mpMRI Rules Out Extra-Prostatic Extension in Prostate Cancer before Robot-Assisted Radical Prostatectomy.
Diagnostics
, 12
(5)
, Article 1057. 10.3390/diagnostics12051057.
|
|
Dinneen, E;
Almeida-Magana, R;
Al-Hammouri, T;
Pan, S;
Leurent, B;
Haider, A;
Freeman, A;
... Shaw, G; + view all
(2025)
Effect of NeuroSAFE-guided RARP versus standard RARP on erectile function and urinary continence in patients with localised prostate cancer (NeuroSAFE PROOF): a multicentre, patient-blinded, randomised, controlled phase 3 trial.
The Lancet Oncology
, 26
(4)
pp. 447-458.
10.1016/S1470-2045(25)00091-9.
|
 |
|
Dinneen, E;
Haider, A;
Allen, C;
Freeman, A;
Briggs, T;
Nathan, S;
Brew-Graves, C;
... Shaw, G; + view all
(2019)
NeuroSAFE robot-assisted laparoscopic prostatectomy versus standard robot-assisted laparoscopic prostatectomy for men with localised prostate cancer (NeuroSAFE PROOF): protocol for a randomised controlled feasibility study.
BMJ Open
, 9
(6)
, Article e028132. 10.1136/bmjopen-2018-028132.
|
 |
|
Dinneen, E;
Haider, A;
Grierson, J;
Freeman, A;
Oxley, J;
Briggs, T;
Nathan, S;
... Shaw, G; + view all
(2020)
NeuroSAFE frozen section during robot-assisted radical prostatectomy (RARP): Peri-operative and Histopathological Outcomes from the NeuroSAFE PROOF Feasibility Randomised Controlled Trial.
BJU International
, 127
(6)
pp. 676-686.
10.1111/bju.15256.
|
|
Kasivisvanathan, V;
Rannikko, AS;
Borghi, M;
Panebianco, V;
Mynderse, LA;
Vaarala, MH;
Briganti, A;
... PRECISION Study Group Collaborators; + view all
(2018)
MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.
The New England Journal of Medicine
10.1056/NEJMoa1801993.
(In press).
|
|
Munro, Alasdair PS;
Feng, Shuo;
Janani, Leila;
Cornelius, Victoria;
Aley, Parvinder K;
Babbage, Gavin;
Baxter, David;
... COV-BOOST study group, .; + view all
(2022)
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
The Lancet Infectious Diseases
10.1016/S1473-3099(22)00271-7.
(In press).
|
|
Shah, Taimur T;
Kanthabalan, Abi;
Otieno, Marjorie;
Pavlou, Menelaos;
Omar, Rumana;
Adeleke, Sola;
Giganti, Francesco;
... Ahmed, Hashim U; + view all
(2022)
Magnetic Resonance Imaging and targeted biopsies compared to transperineal mapping biopsies prior to salvage focal therapy/ablation in localised and metastatic recurrent prostate cancer after radiotherapy. Primary Outcomes from the FORECAST Trial.
European Urology
, 81
(6)
pp. 598-605.
10.1016/j.eururo.2022.02.022.
|
|
Tran, M;
Neves, J;
Stamati, K;
Redondo, P;
Cope, A;
Brew-Graves, C;
Williams, N;
... Emberton, M; + view all
(2019)
Acceptability and feasibility study of patient-specific ‘tumouroids’ as personalised treatment screening tools: protocol for prospective tissue and data collection of participants with confirmed or suspected renal cell carcinoma.
International Journal of Surgery Protocols
, 14
pp. 24-29.
10.1016/j.isjp.2019.03.019.
|
|
